Lung Cancer Considered

Lung Cancer Considered

Por: IASLC
Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda
351 episodios disponibles

Latest episodes of the podcast Lung Cancer Considered

Mostrando página 2 de 18

Lung Cancer Considered--STK11 and KEAP1 as resistance mechanisms to immunotherapy 19/08/2025
LCC in Cantonese: Novel Treatment for Advanced EGFR Mutant Lung Cancer 15/08/2025
FDA Approval: Zongertinib for HER2 Mutant NSCLC 12/08/2025
LCC in Arabic: Arab Women's Voices in Thoracic Oncology 08/08/2025
Artificial Intelligence (AI) and Lung Cancer Treatment Decisions 05/08/2025
Artificial Intelligence (AI) and Lung Cancer Treatment Decisions 05/08/2025
LCC in Romanian: Management of Unresectable, EGFR-mutated Stage III Lung Cancer in Romania 02/08/2025
IASLC - Stigma 29/07/2025
LCC in Japanese: ASCO 2025 Highlights 25/07/2025
Preview: IASLC | ASCO 2025 North American Conference on Lung Cancer 23/07/2025
FDA Approval: Datopotamab Deruxtecan for EGFR NSCLC 18/07/2025
FDA Approval: Sunvozertinib for EGFR Exon 20 15/07/2025
LCC in Portuguese: Virtual Tumor Board - EGFR NSCLC 11/07/2025
IASLC_WCLC 2025 Preview 08/07/2025
Virtual Tumor Board: Resectable EGFR NSCLC 01/07/2025
FDA Approval: Taletrectinib and ROS1 NSCLC 24/06/2025
IASLC - ASCO 2025 Highlights 06/06/2025
FDA Approval: Telisotuzumab Vedotin and MET-Positive NSCLC 27/05/2025
LCC in Korean: Lung Cancer Updates & Future Directions 23/05/2025
Global Advances and Persistent Disparities in Lung Cancer Treatment 20/05/2025
« Primera ‹ Anterior 1 2 3 4 ... 18 Siguiente › Última »
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA